AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for ...

(Reuters) -AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical ...

BTIG notes that shares of Tempus AI (TEM) are up on news that the company signed a $200M expanded strategic agreement with AstraZeneca (AZN) ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

AstraZeneca's Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint ...

AstraZeneca PLC ADR closed 22.59% below its 52-week high of $87.68, which the company achieved on August 30th.

Shares of Tempus AI ( TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

CompanyOverview|NASDAQ:CLLS] Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing ...

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...